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Abstract 
Background :To determine the frequency of 
hematological side effects (anemia, neutropenia and 
thrombocytopenia) during combination therapy with 
interferon and ribavirin in chronic hepatitis C 
patients. 
Methods: In this cross sectional study  228 patients 
of chronic HCVwere included. Patients were given 
injection IFN 3 MIU subcutaneously thrice weekly 
and ribavirin 800 – 1200 mg/day orally. 
Haematological profile was performed in all these  
patients  at weeks 4,12 and 24. Patients who required 
dose reduction or discontinuation of drug were 
excluded form the study 
Results: Overall mean age was 39.6 (±9.2) years 
with male to female  ratio of 2.2: 1. Haematological 
abnormalities were seen in 37.3%. Anaemia (19.3%) 
was the commonest haematological abnormality 
followed by neutropenia(15.6%) and 
thrombocytopenia (9.9%). Multiple side effects were 
seen in 38.5%. 
Conclusion: Amongst the haematological 
disorders anemia and thrombocytopenia were the 
most common and least common respectively during 
the combination therapy of chronic hepatitis C. 
while neutropenia followed as second common 
serious haematological disorder. 
Key Words: HCV, anaemia, neutropenia, 
thrombocytopenia, Interferon, ribavirin. 
 
Introduction 
Hepatitis C Virus (HCV) infection is a global health 
problem. The virus infects approximately 3% of the 
world population; placing approximately 170 million 
people at risk of developing HCV related chronic liver 
disease. 1,2 Currently, chronic hepatitis C infection is 
the most frequent indication for liver transplantation. 
It accounts for estimated 8000 – 10000 deaths each year 
in the United States.3 HCV infection is endemic in 
Pakistan and is a considerable threat to our 
population. 4,5 The prevalence of HCV in Pakistan is 
reported to be 3.29% , 3.3%  and 3.69% in different 
studies.4-6 Cure of chronic hepatitis C in the natural 
course is rare, and the rate of progression to cirrhosis 
and hepatocellular carcinoma is also significantly high. 
The eradication of hepatitis C virus during the chronic 
stage is, therefore, extremely important. 7 
Treatment with pegylated interferon plus ribavirin has 
become the standard of care for patients infected with 
chronic hepatitis C.8 However, standard interferon and 
ribavirin combination is still widely in use in Pakistan 
for chronic hepatitis C infection, because of its low 
cost. Unfortunately, both drugs (interferon and 
ribavirin) have significant hematological toxic effects 
(anaemia, neutropenia and thrombocytopenia).9-11 
 Anaemia during combination therapy for chronic 
hepatitis C begins to develop almost immediately after 
therapy is initiated and becomes most pronounced 
after 4 to 6 weeks of treatment.8 Haemoglobin levels 
do not usually change after week 12 to the completion 
of treatment.7 The values for incidence and severity of 
anemia during combination therapy for chronic 
hepatitis C are higher in Asian studies than in the non-
Asian studies. 10 
    Treatment with interferon and ribavirin combination 
therapy is also associated with neutropenia that is 
more frequent with peg interferon as compared to 
standard interferon.11 A study from the National 
Institutes of Health specifically examined neutropenia 
associated with combination therapy. The mean 
neutrophil count decreased by 34% during the 24 to 48 
week course of therapy and the frequency of 
neutropenia was noted to be 63%. 13 
Thrombocytopenia is another well-known 
complication of antiviral therapy for chronic hepatitis 
C but has been infrequently associated with dose 
reduction or discontinuation.12 During therapy with at 
least one dose of standard or pegylated interferon, 
platelet count decreased by nearly 28%.14 The 
frequency of anemia is reported to be 19.6% and of 
thrombocytopenia to be 13.7% in one study.15 Another 
study stated that hematological side effects were noted 
in 92% of the patients.11  
    Hematological abnormalities are a  common 
indications for dose reduction in chronic hepatitis C 
therapy. Hematological abnormalities accounts for at 
least one dose reduction in approximately 25% of 
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patients during therapy. Dose reductions or premature 
discontinuation results in significantly lower sustained 
virological response.12 As  haematological side effects 
have implications on virological response, therefore, 
knowledge regarding frequency of these side effects is 
of utmost importance. Pakistani population is different 
from Western population in many ways, for example, 
the HCV genotype 1 infection is more common in West 
and genotype 3 infection in Pakistan. Host factors like 
different genetic makeup, difference in immune status 
and lower body mass index (resulting in lesser dose of 
ribavirin required during therapy) for Pakistani 
population may have implications on frequency of the 
hematological side effects of combination therapy. 
There is an enormous difference in the frequencies of 
side effects reported in different studies conducted at 
national level.  
Patients and Methods  
The descriptive study was conducted on patients 
attending the outpatient Department of 
Gastroenterology and Internal Medicine, Ziauddin 
University Hospital; North Campus, Karachi. Sample 
size (n) = 182 + 25% of 182 = 228*;Proportion of 
thrombocytopenia (P) = 13.7% [15] or 0.137 Confidence 
level (1 – α) = 0.05;Margin of error (d) = 5%  
 The sample size was augmented by 25% to cover the 
drop-outs because of dose reduction and drug 
discontinuation. Patients who required dose reduction 
and drug discontinuation were excluded from the 
study. Adult patients with compensated liver disease, 
elevated ALT for more than 6 months and with 
genotype 2 and 3 were included. Exclusion criteria 
were decompensated liver disease, HCV Genotype 1 
(infection with HCV Genotype 1 requires combination 
therapy for 48 weeks. The study was planned to be 
completed in 6 months),co-infection with HBV and 
pregnancy.Paitents who received interferon therapy in 
past were also excluded. Dose reduction or 
discontinuation also lead to exclusion.  
Pre-treatment hemoglobin level less than 13 g/dL in 
males and less than 12 g/dL in females, pre-treatment 
neutrophil count less than 1500 cells/μL and platelet 
count less than 150,000 cells/μL also lead to exclusion.  
Patients were given injection IFN 3 MIU 
subcutaneously thrice weekly and ribavirin 800 – 1200 
mg/day, as per body weight. Those less than 50 kg 
received 800 mg/day, 50 – 75 kg received 1000 mg/kg 
and more than 75 kg received 1200 mg/day. The 
patients were evaluated at week 4, 12 and 24 and 
blood was drawn for complete blood counts. Dose of 
the interferon and/or ribavarin was reduced for any 
patient in whom hemoglobin level fell below 10 g/dL 
and/or neutrophil count dropped below 750 cells/μL 
and/or platelet count below 50,000 cells/μL during 
the course of treatment. The therapy was discontinued 
in the patients in whom hemoglobin level dropped 
below 8.5 g/dL and/or neutrophil count  below 500 
cells/μL and/or platelet count below 30,000 cells/μL. 
These criteria for dose reduction and drug 
discontinuation were in accordance with the 
guidelines for treatment of chronic hepatitis C. The 
patients who required dose reduction or drug 
discontinuation during the course of treatment were 
excluded from the study. The final outcome was 
measured at week 24, when the values for 
haemoglobin level, neutrophil count and platelet count 
were recorded. The patient was said to have 
developed anaemia if the haemoglobin level fell below 
13 g/dL in males and less than 12 g/dL in females, 
neutropenia if neutrophil count fell below 1500 
cells/μL and thrombocytopenia if platelet count fell 
below 1,50,000 cells/μL.  
 
Results 
 A total of 228 patients with chronic hepatitis C were 
included in this study. Sixteen (7.02%) of the patients 
were excluded due to dose modification or 
discontinuation during the follow-up period. Due to 
anemia dose was reduced in 6 and discontinued in 4 
cases, due to neutropenia dose was reduced in 3 and 
discontinued in 1 case and in thrombocytopenia dose 
was reduced in 2 cases.Mean (±SD) age of patients 
was39.6 (±9.2) years with range = 18 – 50 years. 
Majority of cases 113 (53.3%) had age between 20 – 40 
years. Gender distribution showed male 
preponderance (male: female = 2.2: 1), 145 (68.4%) 
were males and 67 (31.6%) were females (Table 1). 
 
Table 1: Hepatiis C and Combination therapy  -
Demographic profile 
Sex  Male 145 (68.4%) 
Female 67 (31.6%) 
M:F ratio 2.2:1 
Age (Years)  Less than 20 7 (3.3%) 
20-40 113(53.3%) 
>40 92 (43.4%) 
 
 Seventy Nine (37.3%) patients developed significant 
hematological abnormalities during treatment with 
interferon and ribavirin. Anemia was the most 
common type of hematological abnormalities 
developed in 41 (19.3%) cases followed by neutropenia 
in 33 (15.6%) cases and thrombocytopenia in 21 (9.9%) 
cases. Proportions of hematological abnormalities were 
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similar in both genders. Fifty five (37.9%) were male 
and 24 (35.8%) were female. Majority of the patients 
were in age group 20 to 40 years. Anaemia (19.3%) 
was the commonest side effect (Table 2). Multiple 
effects were seen in 38.5% (Table 3). 
 
Table 2:Hepatitis C and Combination Therapy- 
Haematological Profile 
Variable No(%) 
Overall distribution (n=212) 
Normal 133(62.7%) 
Patients with 
Haematological side 
effects 
79 (37.3%) 
Haematological side effects – sex profile (n=79) 
Male 55 (37.9%) 
Female 24 (35.8%) 
Haematological side effects – age profile (n=79) 
Less than 20 years 2 (2.5%) 
20-40 years 51 (56.6%) 
>40 years 26 (28.9%) 
Haematological side effects (n=79) 
Anaemia 41 (19.3%) 
Thrombocytopenia 21 (9.9%) 
Neutropenia 33 (  15.6%) 
Multiple effects 16 (38.5%) 
Table 3:Haematological side effects  according  
to  gender 
Side Effects  Male Female 
Anaemia 29 (52.7%) 12 (50%) 
Neutropenia 23 (41.8%) 10 (41.7%) 
Thrombocytopenia 15 (27.3%) 6 (25%) 
Multiple Effects 12 (21.8%) 4 (16.7%) 
 
Discussion 
    The treatment of CHC is now well established with 
conventional interferon or pegylated interferon in 
combination with ribavirin.20 One of the main 
drawbacks of this combination therapy is the 
development of side effects, which can result in 
suboptimal dosing or discontinuation of therapy. This 
can limit the likelihood of serological viral response 
(SVR), since one of the determinants of SVR is 
adequate dose and duration of therapy. Among the 
side effects of combination therapy, hematologic 
abnormalities such as anemia, neutropenia, and 
thrombocytopenia have been reported to result in dose 
reduction and discontinuation of therapy in up to 25% 
and 3% of patients, respectively.13-20 
The withdrawal rate increases with both the duration 
of treatment and use of combination therapy.16 The 
withdrawal rate for combination therapy is lower 
when therapy is administered for  24 weeks.21  
In present study 37.3% of the patients developed 
significant haematological abnormalities during 
treatment with interferon and ribavirin and 7.02% 
were excluded due to drug modification or 
discontinuation during the follow-up period. A study 
from USA reported 38.2% of the cases developed 
haematological side effects during the combination 
therapy, a figure similar to what is seen in present 
study.22 Another study conducted in Pakistan reported 
92% mild to moderate haematological side effect 
during the combination therapy. 11 
In this study anaemia was the most common type of 
haematological abnormality seen in 19.3% of cases 
followed by neutropenia in 15.6% and 
thrombocytopenia in 9.9% cases. Study from USA 
reported 20.6%, 22.1%, and 8.1% developed 
neutropenia, anaemia, and thrombocytopenia, 
respectively.22 In another study from Pakistan, mild to 
moderate anaemia was noted in 70 % of the patients.11 
Anaemia is caused both by interferon due to 
myelosupression and ribivirin causing hemolysis.18,19 
In same study mild to moderate neutropenia was 
reported in 64% of cases and thrombocytopenia in 61% 
of patients.10 Neutropenia is one of the expected side 
effects of combination therapy but the risk of the 
serious infection is very low even with severe 
neutropenia.13 In clinical  practice thrombocytopenia 
does not pose significant problem. 12 
Hematologic abnormalities are common during 
combination antiviral therapy for chronic hepatitis C. 
Although dose reduction or discontinuation is done to 
overcome these side effects, they can adversely affect 
the efficacy of combination antiviral therapy. This is 
especially true in the cases of ribavirin induced 
anemia. Recent evidence has led to increasing 
recognition that optimal dosing of ribavirin is a crucial 
determinant of viral clearance. Preliminary data 
suggest that hematopoietic growth factors may be 
useful for managing the hematologic side effects of 
combination therapy (especially anemia). 
 
Conclusion 
1. Haematological side effects are a common 
occurrence in  patients receiving combination 
therapy for hepatitis C. 
2. Haematopoietic growth factors in cases with 
haematological cytopenias can augment the 
counts.    
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